KALOR DESIGN 彩研設計製作

Pillar Biosciences Strengthens Leadership Team with Appointment of Vincent Ricci as Chief Financial Officer

Pillar Biosciences Strengthens Leadership Team with Appointment of Vincent Ricci as Chief Financial Officer June 8, 2022 Home  >  Resources  >  Press Release  >  Pillar Biosciences Strengthens Leadership Team with Appointment of Vincent Ricci as Chief Financial Officer NATICK, Mass. – June 8, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and overall testing costs, today announced the appointment of Vincent Ricci as Chief Financial Officer. Mr. Ricci will lead Pillar Bioscience’s finance and investor relations functions as the company …

Pillar Biosciences Strengthens Leadership Team with Appointment of Vincent Ricci as Chief Financial Officer Read more »

Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology

Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology May 31, 2022 Home  >  Resources  >  Press Release  > Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology Study entitled “Reducing Pre-analytical Sample QC Failure Rates for Cancer Molecular Genetic Assays with SLIMamp® Technology” published in conjunction with the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting NATICK, Mass. – May 31, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation …

Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology Read more »

Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants

Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants April 11, 2022 Home  >  Resources  >  Press Release  > Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants – Laboratory and software validation testing determined ability to accurately identify key companion diagnostic targets within KRAS and EGFR genes, and specify associated approved therapy – These data, plus three additional studies, presented at the 2022 American Association for Cancer Research (AACR) …

Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants Read more »

AMDL received certificate of CAP EQAP 2021

In Mar 2022, AMDL received certificate of CAP EQAP 2021 March, 2022 Home  >  Resources  >  Press Release  >  In Mar 2022, AMDL received certificate of CAP EQAP 2021 Good news! AMDL Molecular Laboratory passed CAP-PT(NGSST) with full marks.

Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel

Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counse March 8, 2022 Home  >  Resources  >  Press Release  > Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counse NATICK, Mass. – March 8, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced the appointment of Daniel Harma, M.B.A., as Chief Commercial Officer and Christa Adkins, J.D., as General Counsel. Both executives join Pillar Biosciences with more than 20 …

Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel Read more »

AMDL launched the Cancer Diagnostic Test

AMDL launched the Cancer Diagnostic Test Feb, 2022 Home  >  Resources  >  Press Release  > AMDL launched the Cancer Diagnostic Test We are delighted and proud to announce that, after a long preparation of our laboratory, we have launched our First AMDL Lung and Colorectal Cancer Genetic Test!If you are interested, please feel free to contact and email us for the details of our service. Get One Step Ahead of Cancer Contact us

Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference February 10, 2022 Home  >  Resources  >  Press Release  > Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference NATICK, Mass. – February 10, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced that Randy Pritchard, Chief Executive Officer, will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 16, 2022, at 12:30pm Eastern Time. About Pillar Biosciences Pillar …

Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Read more »

Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory

Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory January 6, 2022 Home  >  Resources  >  Press Release  > Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory NATICK, Mass. – January 6, 2022 – (BUSINESS WIRE) – Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced that its NGS laboratory, located in Natick, Massachusetts, has passed the onsite inspection and received Clinical Laboratory Improvement Amendment (CLIA) certification from the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS), as well as the Massachusetts state permit. …

Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory Read more »

Pillar Biosciences received premarket approval from FDA for its ONCO/Reveal™ Dx Lung and Colon Cancer Assay

Pillar Biosciences received premarket approval from FDA for its ONCO/Reveal™ Dx Lung and Colon Cancer Assay Aug, 2021 Home  >  Resources  >  Press Release  > Pillar Biosciences received premarket approval from FDA for its ONCO/Reveal™ Dx Lung and Colon Cancer Assay Pillar Biosciences announced the U.S. Food and Drug Administration (FDA) has given Premarket Approval (PMA) to its ONCO/Reveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the qualitative detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors. Please click here for details.

Renovation of molecular diagnostic laboratory in HKSTP finished

Renovation of molecular diagnostic laboratory in HKSTP finished Jul, 2020 Home  >  Resources  >  Press Release  > Renovation of molecular diagnostic laboratory in HKSTP finished Joined Hong Kong Science and Technology (HKSTP) as a Tenant company and started to build a molecular diagnostic laboratory in HKSTP. AMDL started its centralized laboratory in the HKSTP, where it is a hub of talents and innovations in R&D industry in Hong Kong. We hope to encounter more opportunities with the world-class developers here.

Scroll to Top